Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04837209
Title Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Therapies

Dostarlimab-gxly + Niraparib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.